Voyager Therapeutics, Inc. Revenue
Voyager Therapeutics, Inc. (VYGR) reported Revenue of $3.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $3.17M, a 39.13% decline year-over-year.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.59M, a 59.94% decline year-over-year.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $15.34M, a 144.28% increase year-over-year.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $13.37M, a 45.73% decline year-over-year.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $40.37M, a 49.53% decline from fiscal 2024.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $80.00M, a 68.00% decline from fiscal 2023.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $250.01M, a 511.16% increase from fiscal 2022.
- Voyager Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $40.91M, a 9.33% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.17M 10-Q · filed 2026-08-06 | $5.76M 10-Q · filed 2026-08-06 | $21.09M derived: sum of 3 quarters · filed 2026-08-06 | $34.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.59M 10-Q · filed 2026-05-07 | $17.93M derived: sum of 2 quarters · filed 2026-05-07 | $31.29M derived: sum of 3 quarters · filed 2026-05-07 | $36.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $28.70M derived: sum of 2 quarters · filed 2026-03-09 | $33.90M derived: sum of 3 quarters · filed 2026-08-06 | $40.37M 10-K · filed 2026-03-09 |
| 2025-09-30 | $13.37M 10-Q · filed 2025-11-10 | $18.57M derived: sum of 2 quarters · filed 2026-08-06 | $25.04M 10-Q · filed 2025-11-10 | $31.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.20M 10-Q · filed 2026-08-06 | $11.67M 10-Q · filed 2026-08-06 | $17.95M derived: sum of 3 quarters · filed 2026-08-06 | $42.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.47M 10-Q · filed 2026-05-07 | $12.75M derived: sum of 2 quarters · filed 2026-05-07 | $37.38M derived: sum of 3 quarters · filed 2026-05-07 | $66.96M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $30.91M derived: sum of 2 quarters · filed 2026-03-09 | $60.48M derived: sum of 3 quarters · filed 2026-03-09 | $80.00M 10-K · filed 2026-03-09 |
| 2024-09-30 | $24.63M 10-Q · filed 2025-11-10 | $54.21M derived: sum of 2 quarters · filed 2025-11-10 | $73.72M 10-Q · filed 2025-11-10 | $163.78M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $29.58M 10-Q · filed 2025-08-06 | $49.09M 10-Q · filed 2025-08-06 | $139.16M derived: sum of 3 quarters · filed 2026-03-09 | $143.77M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $19.52M 10-Q · filed 2025-05-06 | $109.58M derived: sum of 2 quarters · filed 2026-03-09 | $114.19M derived: sum of 3 quarters · filed 2026-03-09 | $119.04M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $90.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $94.67M derived: sum of 2 quarters · filed 2026-03-09 | $99.53M derived: sum of 3 quarters · filed 2026-03-09 | $250.01M 10-K · filed 2026-03-09 |
| 2023-09-30 | $4.61M 10-Q · filed 2024-11-12 | $9.47M derived: sum of 2 quarters · filed 2024-11-12 | $159.95M 10-Q · filed 2024-11-12 | $158.40M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $4.85M 10-Q · filed 2024-08-06 | $155.33M 10-Q · filed 2024-08-06 | $153.78M derived: sum of 3 quarters · filed 2025-03-11 | $194.87M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $150.48M 10-Q · filed 2024-05-13 | $148.93M derived: sum of 2 quarters · filed 2025-03-11 | $190.02M derived: sum of 3 quarters · filed 2025-03-11 | $190.73M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $39.54M derived: sum of 2 quarters · filed 2025-03-11 | $40.25M derived: sum of 3 quarters · filed 2025-03-11 | $40.91M 10-K · filed 2025-03-11 |
| 2022-09-30 | $41.09M 10-Q · filed 2023-11-06 | $41.80M derived: sum of 2 quarters · filed 2023-11-06 | $42.46M 10-Q · filed 2023-11-06 | $70.53M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $712.00K 10-Q · filed 2023-08-03 | $1.37M 10-Q · filed 2023-08-03 | $29.44M derived: sum of 3 quarters · filed 2024-02-28 | $30.93M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $658.00K 10-Q · filed 2023-05-09 | $28.73M derived: sum of 2 quarters · filed 2024-02-28 | $30.21M derived: sum of 3 quarters · filed 2024-02-28 | $31.57M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $28.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $29.55M derived: sum of 2 quarters · filed 2024-02-28 | $30.91M derived: sum of 3 quarters · filed 2024-02-28 | $37.41M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.48M 10-Q · filed 2022-11-08 | $2.84M derived: sum of 2 quarters · filed 2022-11-08 | $9.34M 10-Q · filed 2022-11-08 | $15.88M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $1.36M 10-Q · filed 2022-08-04 | $7.86M 10-Q · filed 2022-08-04 | $14.39M derived: sum of 3 quarters · filed 2023-03-07 | $132.24M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $6.50M 10-Q · filed 2022-05-04 | $13.04M derived: sum of 2 quarters · filed 2023-03-07 | $130.88M derived: sum of 3 quarters · filed 2023-03-07 | $159.56M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $124.38M derived: sum of 2 quarters · filed 2023-03-07 | $153.06M derived: sum of 3 quarters · filed 2023-03-07 | $171.13M 10-K · filed 2023-03-07 |
| 2020-09-30 | $117.84M 10-Q · filed 2021-11-02 | $146.52M derived: sum of 2 quarters · filed 2021-11-02 | $164.59M 10-Q · filed 2021-11-02 | $197.26M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $28.68M 10-Q · filed 2021-08-09 | $46.75M 10-Q · filed 2021-08-09 | $79.42M derived: sum of 3 quarters · filed 2021-08-09 | $99.86M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $18.07M 10-Q · filed 2021-05-10 | $50.74M derived: sum of 2 quarters · filed 2021-05-10 | $71.17M derived: sum of 3 quarters · filed 2021-05-10 | $117.26M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $32.67M 10-K · filed 2020-03-03 | $53.11M derived: sum of 2 quarters · filed 2020-11-09 | $99.19M derived: sum of 3 quarters · filed 2020-11-09 | $104.39M 10-K · filed 2022-03-08 |
| 2019-09-30 | $20.43M 10-Q · filed 2020-11-09 | $66.52M derived: sum of 2 quarters · filed 2020-11-09 | $71.72M 10-Q · filed 2020-11-09 | $73.72M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $46.09M 10-Q · filed 2020-08-10 | $51.28M 10-Q · filed 2020-08-10 | $53.29M derived: sum of 3 quarters · filed 2020-08-10 | $55.39M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $5.20M 10-Q · filed 2020-05-06 | $7.21M derived: sum of 2 quarters · filed 2020-05-06 | $9.30M derived: sum of 3 quarters · filed 2020-05-06 | $11.87M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $2.01M 10-K · filed 2020-03-03 | $4.10M derived: sum of 2 quarters · filed 2020-03-03 | $6.68M derived: sum of 3 quarters · filed 2020-03-03 | $7.62M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.09M 10-K · filed 2020-03-03 | $4.67M derived: sum of 2 quarters · filed 2020-03-03 | $5.61M 10-Q · filed 2019-11-06 | $11.96M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $2.58M 10-K · filed 2020-03-03 | $3.52M 10-Q · filed 2019-08-09 | $9.86M derived: sum of 3 quarters · filed 2020-03-03 | $11.01M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $942.00K 10-K · filed 2020-03-03 | $7.29M derived: sum of 2 quarters · filed 2020-03-03 | $8.44M derived: sum of 3 quarters · filed 2020-03-03 | $9.61M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $6.35M 10-K · filed 2019-02-26 | $7.49M derived: sum of 2 quarters · filed 2019-02-26 | $8.67M derived: sum of 3 quarters · filed 2019-02-26 | $10.13M 10-K · filed 2020-03-03 |
| 2017-09-30 | $1.15M 10-K · filed 2019-02-26 | $2.33M derived: sum of 2 quarters · filed 2019-02-26 | $3.79M derived: sum of 3 quarters · filed 2019-02-26 | |
| 2017-06-30 | $1.18M 10-K · filed 2019-02-26 | $2.64M derived: sum of 2 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $1.46M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $14.22M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |